S&P 500   2,987.58 (-0.27%)
DOW   27,005.06 (-0.07%)
QQQ   192.73 (-0.41%)
AAPL   233.71 (-0.68%)
FB   188.76 (-0.07%)
MSFT   139.91 (-1.17%)
GOOGL   1,243.42 (+0.09%)
AMZN   1,775.51 (+0.46%)
CGC   19.94 (-0.80%)
NVDA   195.18 (-0.61%)
MU   45.58 (-1.89%)
BABA   176.22 (+0.53%)
GE   8.95 (+0.67%)
TSLA   260.22 (+0.90%)
AMD   30.88 (+0.52%)
ACB   3.70 (-1.60%)
NFLX   282.62 (-0.57%)
DIS   131.13 (+1.06%)
S&P 500   2,987.58 (-0.27%)
DOW   27,005.06 (-0.07%)
QQQ   192.73 (-0.41%)
AAPL   233.71 (-0.68%)
FB   188.76 (-0.07%)
MSFT   139.91 (-1.17%)
GOOGL   1,243.42 (+0.09%)
AMZN   1,775.51 (+0.46%)
CGC   19.94 (-0.80%)
NVDA   195.18 (-0.61%)
MU   45.58 (-1.89%)
BABA   176.22 (+0.53%)
GE   8.95 (+0.67%)
TSLA   260.22 (+0.90%)
AMD   30.88 (+0.52%)
ACB   3.70 (-1.60%)
NFLX   282.62 (-0.57%)
DIS   131.13 (+1.06%)
Log in

Omeros Stock Price, News & Analysis (NASDAQ:OMER)

-0.02 (-0.13 %)
(As of 10/16/2019 01:32 PM ET)
Today's Range
Now: $15.48
50-Day Range
MA: $17.39
52-Week Range
Now: $15.48
Volume7,785 shs
Average Volume372,595 shs
Market Capitalization$763.01 million
P/E RatioN/A
Dividend YieldN/A
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:OMER



Sales & Book Value

Annual Sales$29.87 million
Book Value($2.04) per share


Net Income$-126,760,000.00
Net Margins-135.46%


Market Cap$763.01 million
Next Earnings Date11/14/2019 (Estimated)

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

Omeros (NASDAQ:OMER) Frequently Asked Questions

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) announced its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Zacks' consensus estimate of ($0.44) by $0.15. The biopharmaceutical company earned $26.80 million during the quarter, compared to analysts' expectations of $25.33 million. Omeros's revenue for the quarter was up 1476.5% on a year-over-year basis. During the same period last year, the firm earned ($0.70) earnings per share. View Omeros' Earnings History.

When is Omeros' next earnings date?

Omeros is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Omeros.

What price target have analysts set for OMER?

4 Wall Street analysts have issued twelve-month price objectives for Omeros' stock. Their forecasts range from $18.00 to $35.00. On average, they expect Omeros' stock price to reach $27.75 in the next year. This suggests a possible upside of 79.0% from the stock's current price. View Analyst Price Targets for Omeros.

What is the consensus analysts' recommendation for Omeros?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omeros.

What are Wall Street analysts saying about Omeros stock?

Here are some recent quotes from research analysts about Omeros stock:
  • 1. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (10/16/2019)
  • 2. HC Wainwright analysts commented, "We note that the performance vs. consensus was substantially more impressive, as Omeros delivered top-line results that were $6M ahead of consensus estimates and bottom-line numbers that were $0.26 better than consensus. Management indicated on its earnings conference call the strong year-end performance of OMIDRIA, which is currently covered for nearly 90% of relevant lives and which is on a $100M annualized revenue run rate as of December 2018. Investors should note that we expect OMIDRIA revenue to meaningfully accelerate over the course of this year and well into 2020, with our full-year 2019 revenue projection currently at $165.4M and 2020 top-line revenue estimated at $242.3M. Given the strength of the OMIDRIA franchise and the potential for multiple near-term pipeline catalysts, notably the start of a possible regulatory filing in the U.S." (3/4/2019)

Has Omeros been receiving favorable news coverage?

Media stories about OMER stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Omeros earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Omeros.

Who are some of Omeros' key competitors?

What other stocks do shareholders of Omeros own?

Who are Omeros' key executives?

Omeros' management team includes the folowing people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 60)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 61)
  • Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 59)
  • Dr. Pamela Pierce Palmer, Co-Founder (Age 56)
  • Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 62)

Who are Omeros' major shareholders?

Omeros' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (10.19%) and Cypress Capital Group (0.06%). Company insiders that own Omeros stock include Marcia S Kelbon and Michael A Jacobsen. View Institutional Ownership Trends for Omeros.

Which major investors are buying Omeros stock?

OMER stock was purchased by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC and Cypress Capital Group. View Insider Buying and Selling for Omeros.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $15.50.

How big of a company is Omeros?

Omeros has a market capitalization of $764.00 million and generates $29.87 million in revenue each year. The biopharmaceutical company earns $-126,760,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Omeros employs 236 workers across the globe.View Additional Information About Omeros.

What is Omeros' official website?

The official website for Omeros is http://www.omeros.com/.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.

MarketBeat Community Rating for Omeros (NASDAQ OMER)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  646 (Vote Outperform)
Underperform Votes:  411 (Vote Underperform)
Total Votes:  1,057
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: Day Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel